Evidence map›Paper›PMID 42460291›Full record

ArticlePreventive medicine reports2026

Monitoring of tobacco product marketing for rapid public health surveillance in the United States.

Ollie Ganz, Jon-Patrick Allem, Meagan O Robichaud, Eugene M Talbot, Kristopher Roberts, Patrick V Barnwell, Scott I Donaldson, Cristine D Delnevo

Abstract read
In one paragraph

Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ollie GanzRutgers Institute for Nicotine and Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA.
Jon-Patrick AllemRutgers Institute for Nicotine and Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA.
Meagan O RobichaudRutgers Institute for Nicotine and Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA.
Eugene M TalbotRutgers Institute for Nicotine and Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA.
Kristopher RobertsRutgers Institute for Nicotine and Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA.
Patrick V BarnwellRutgers Institute for Nicotine and Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA.
Scott I DonaldsonRutgers Institute for Nicotine and Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA.
Cristine D DelnevoRutgers Institute for Nicotine and Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA.

Funding

Rutgers Center of Excellence in Rapid Surveillance of TobaccoU01CA278695 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI CRISTINE D DELNEVO, Ollie Ganz · 2023 to 2026
$14.0M
NCI NIH HHS U01 CA278695
6 · The paper itself

Abstract

The US tobacco landscape is constantly changing, with the commercial tobacco industry regularly flooding the market with new brands, flavors, and styles. Rutgers Center for Rapid Surveillance of Tobacco (CRST) examines tobacco product marketing, the tobacco product marketplace, and tobacco use behaviors. This paper describes how findings from tobacco marketing surveillance are integrated with other data sources to provide timely and actionable information about changes in tobacco products to inform the U.S. Food and Drug Administration's (FDA) regulatory efforts that reduce tobacco harms. CRST conducts regular surveillance of consumer-facing advertisements via print and online, business-to-business publications, direct-to-consumer marketing, branded tobacco company websites, and social media posts for over 50 brands. Information is disseminated through publication in peer-reviewed journals, public fact sheets, and weekly online newsletters to stakeholders. Geek Bar, an e-cigarette brand, illustrates how findings from CRST tobacco marketing surveillance are triangulated with data from other CRST activities to provide rapid information on an emerging brand. The presence of the brand was identified as a signal of interest in early sales data, whereafter surveillance of the brand's marketing activities showed frequent product releases and marketing targeting young people. This systematic tobacco marketing surveillance, when combined with other CRST activities, keeps regulators and the public health community informed in a constantly changing marketplace. CRST findings help to identify tobacco and nicotine products that pose the greatest threat to population health.

Indexed as

Social mediaTobaccoTobacco advertisingTobacco marketingTobacco regulatory science

Identifiers

PMID42460291
PMCPMC13370814

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.